SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Meredith Bernhard discussing the oncologic efficacy of reduced versus standard-dose BCG for non muscle invasive ...
The future of Web3 isn’t just about Real-World Assets (RWAs), it’s about Real Women Assets leading the charge. In an industry ...
ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...
According to research by BCG and B Capital, India’s digital healthcare industry, valued at $2.7 billion in 2022, could expand ...
We looked at every winning NCAA bracket since 2015 to find what it was that helped the likes of mjbrewer and KELSEY 2017 beat ...
A safe vaccine called BCG, consisting of a weakened strain of the closely related Mycobacterium bovis, has been available for over a century.(AP) Two preclinical research addresses the difficulty ...
A research team has developed an innovative nanomotor-based strategy to improve immunotherapy for bladder cancer. The study, published in the journal Nature Communications, offers a promising ...
The company holds several patents for the composition and use of BCG combined with Anktiva in bladder cancer treatment. Credit: SaiArLawKa2/Shutterstock. ImmunityBio ...
The authorization was granted to ImmunityBio, the manufacturer of Anktiva ® (nogapendekin alfa inbakicept-pmln), an interleukin-15 receptor agonist, indicated with BCG for adult patients with BCG ...
Genome-scale metabolic reconstruction of urinary microbiome: Pathway for personalized medicine. Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback